Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Aura Biosciences, Inc.
ForGrowth III PA B.V. has filed a Schedule 13G, reporting a new beneficial ownership stake in Aura Biosciences, Inc. This filing confirms the investor's significant equity position in the company.…more
Aura Biosciences, Inc.
Julie Person, a director at Aura Biosciences, filed a Power of Attorney on August 31, 2026, delegating SEC reporting responsibilities to designated agents. This authorization grants Amy Elazzouzi and Daniel Grassi the authority to prepare and file SEC Forms 3, 4, 5, and Rule 144 documents on her behalf.…more
Aura Biosciences, Inc.
Erica Kratz, an executive at Aura Biosciences, has filed a Power of Attorney appointing Amy Elazzouzi and Daniel Grassi as her attorneys-in-fact for SEC reporting purposes. This authorization grants the designated agents the power to prepare and file Forms 3, 4, 5, and Rule 144 documents regarding her company stock ownership and transactions.…more
16 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
Aura Biosciences to Participate in Investor Conference
Aura Biosciences announced that its CEO will participate in the upcoming Morgan Stanley Global Healthcare Conference. This is a routine investor relations event and does not provide immediate material impact on the stock.…more
●●●●●●●● ●●●●● ●●●●●●
Aura Biosciences announced the grant of stock options and restricted stock units to its newly appointed Chief Regulatory and Quality Officer, COO, and Chief People Officer. This move represents a standard executive compensation package following recent leadership appointments.…more
●●●●●●●● ●●●●● ●●●●●●
아우라 바이오사이언스는 핵심 파이프라인인 안과 종양 치료제 개발에 집중하기 위해 인력의 약 20%를 감원하는 구조조정을 발표했습니다. 이번 조치로 확보된 자금은 2029년 상반기까지 운영 자금으로 활용되며, 임상 3상 시험 등 주요 개발 과제에 집중될 예정입니다.…more
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.